Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
Speciality pharmaceutical firm Alliance Pharma has conditionally agreed to buy Cambridge Laboratories (Ireland) and Cambridge Laboratories for between 14.3m and 16.4m plus the value of inventory.
Completion is expected on 22 February. The acquisition includes 18 prescription products across a range of therapeutic areas, including:
* ImmuCyst, an immunotherapy for superficial bladder cancer.
* Gelclair, an oral gel for the management of oral mucositis caused by chemotherapy and radiotherapy.
*Procarbazine, a treatment of Hodgkin's Lymphoma as part of chemotherapy treatment.
* Aa liquid formulation of Vitamin E, the only one licensed in the UK.
Alliance is raising 7.5m through a conditional placing and Lloyds Banking Group is providing an additional 4m term loan and has increased the existing 5m working capital facility to 6m.
Story provided by Business Financial Newswire
Shares in British banks rose on the FTSE 100 in morning trading following positive news on the Greek debt crisis.
Unite, the union, has gone to international unions, in its attempts to bring the...
© 2010 The IBTimes Company Ltd. All Rights Reserved.
Partners 
EMAIL
PRINT
RSS
SHARE
